Table 1 Characteristics of the patients at baseline included in this study

Age, average ± SD (years)

12.5 ± 10.8

11.7 ± 10.8

0.509^a

Age group, n (%)

0.175^b

 0–5 years

69 (14.8%)

14 (12.1%)

 6–18 years

345 (74.2%)

95 (81.9%)

  ≥ 19 years

51 (11.0%)

7 (6.0%)

Gender, n (%)

0.104^b

 Male

262 (56.3%)

55 (47.4%)

 Female

203 (43.7%)

61 (52.6%)

Treatment, n (%)

0.126^b

 Baloxavir

189 (40.6%)

39 (33.6%)

 Laninamivir

58 (12.5%)

10 (8.6%)

 Oseltamivir

181 (38.9%)

52 (44.8%)

 Zanamivir

37 (8.0%)

15 (12.9%)

Vaccination status, n (%)

 < 0.001^b

 Unvaccinated

235 (50.5%)

81 (69.8%)

 Vaccinated

230 (49.5%)

35 (30.2%)

Drug resistance substitution, n (%)

 NA/H275Y

0 (0.0%)

0 (0.0%)

 PA variants

21 (4.5%)

NA

Viral RNA shedding, average ± SD (log₁₀ copies/µL)

 First visit

4.2 ± 1.3

3.5 ± 0.9

 < 0.001^c

 Second Visit

1.0 ± 1.4

1.0 ± 1.3

0.860^a

Interval time, Median (IQR) (day)

 From onset to first visit

1 (0–1)

1 (0–1)

0.008^d

 From onset to second visit

5 (4–5)

5 (4–5)

0.966^d